{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-076339","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2024-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.466062+00:00","generated_at":"2026-06-01T02:52:26.795029+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amylyx acquires Avexitide from bankrupt Eiger BioPharma for $35.1M","bullets":["Acquires substantially all assets for Avexitide, a GLP-1 receptor antagonist, from Eiger BioPharmaceuticals.","Total purchase price $35.1M plus determined cure costs capped at $277,703.63.","Transaction subject to Bankruptcy Court approval; Eiger filed Chapter 11 on April 1, 2024.","Deal includes assigned contracts and regulatory filings; closing expected after court order.","Amylyx deposits $1.755M into escrow as deposit per approved bid procedures."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-076339","json":"https://secwatch.observer/filing/0000950170-24-076339.json","markdown":"https://secwatch.observer/filing/0000950170-24-076339.md","text":"https://secwatch.observer/filing/0000950170-24-076339.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024076339/0000950170-24-076339-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024076339/amlx-20240621.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:52:26.795029+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}